Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: An effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
BJU International, ISSN: 1464-4096, Vol: 104, Issue: 5, Page: 633-639
2009
- 30Citations
- 51Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations30
- Citation Indexes27
- 27
- CrossRef14
- Policy Citations2
- Policy Citation2
- Clinical Citations1
- PubMed Guidelines1
- Captures51
- Readers51
- 51
Article Description
Objective To determine whether the new fluoroquinolone prulifloxacin might improve tolerance to Bacillus Calmette-Guérin (BCG) intravesical therapy in patients with bladder cancer. PATIENTS AND Methods A series of 72 patients with intermediate- or high-risk nonmuscle-invasive bladder cancer were enrolled in this prospective, randomized, open-label, controlled clinical trial performed at a single tertiary care institution. After complete transurethral resection, patients were randomized to receive induction treatment with BCG and three capsules of prulifloxacin 600 mg or no prophylactic treatment (control group). Adverse events (AEs) were self-recorded by the patients after each instillation and classified by the investigator according to a classification grid considering account duration and intensity. Cystoscopy findings at 3 and 6 months were also recorded. Results There was no significant difference in baseline symptoms between the groups. Overall, there was a significant decrease in the percentage of patients with at least one AE between instillations in prulifloxacin-treated group. The proportion of patients with moderate to severe AEs after the fourth instillation was significantly less in the prulifloxacin-treated group. There was a significant effect of prulifloxacin on the need for anti-tuberculosis treatment. More patients in the control group stopped or delayed the full induction course of BCG instillations (34% vs 19%, P = 0.04). Recurrence rates were not affected by prulifloxacin treatment. Conclusion Prulifloxacin reduces the incidence of moderate to severe AEs from BCG intravesical therapy in patients with nonmuscle-invasive bladder cancer, improving compliance to the induction BCG course. These preliminary findings warrant further clinical research. © 2009 BJU International.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=68849094563&origin=inward; http://dx.doi.org/10.1111/j.1464-410x.2009.08469.x; http://www.ncbi.nlm.nih.gov/pubmed/19298412; http://doi.wiley.com/10.1111/j.1464-410X.2009.08469.x; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1464-410X.2009.08469.x; https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2009.08469.x; https://dx.doi.org/10.1111/j.1464-410x.2009.08469.x; https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2009.08469.x
Wiley-Blackwell
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know